Johnson & Johnson (JNJ)vsTeck Resources Ltd Class B (TECK)
JNJ
Johnson & Johnson
$221.32
-0.53%
HEALTHCARE · Cap: $535.63B
TECK
Teck Resources Ltd Class B
$60.76
-2.02%
BASIC MATERIALS · Cap: $29.77B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 677% more annual revenue ($96.36B vs $12.41B). JNJ leads profitability with a 21.8% profit margin vs 14.9%. JNJ appears more attractively valued with a PEG of 2.92. TECK earns a higher WallStSmart Score of 73/100 (B).
JNJ
Buy59
out of 100
Grade: C
TECK
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-38.5%
Fair Value
$160.72
Current Price
$221.32
$60.60 premium
Margin of Safety
+9.1%
Fair Value
$66.42
Current Price
$60.76
$5.66 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Strong operational efficiency at 39.8%
Revenue surging 72.2% year-over-year
Earnings expanding 128.8% YoY
Reasonable price relative to book value
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Grey zone — moderate risk
ROE of 5.9% — below average capital efficiency
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : TECK
The strongest argument for TECK centers on Operating Margin, Revenue Growth, EPS Growth. Revenue growth of 72.2% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : TECK
The primary concerns for TECK are Altman Z-Score, Return on Equity, PEG Ratio.
Key Dynamics to Monitor
JNJ profiles as a mature stock while TECK is a growth play — different risk/reward profiles.
TECK carries more volatility with a beta of 1.57 — expect wider price swings.
TECK is growing revenue faster at 72.2% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
TECK scores higher overall (73/100 vs 59/100) and 72.2% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Teck Resources Ltd Class B
BASIC MATERIALS · OTHER INDUSTRIAL METALS & MINING · USA
Teck Resources Limited is dedicated to exploring, acquiring, developing and producing natural resources in Asia, Europe and North America. The company is headquartered in Vancouver, Canada.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?